Pharmacogenomics of Hypertension: A Genome‐Wide, Placebo‐Controlled Cross‐Over Study, Using Four Classes of Antihypertensive Drugs. Issue 1 (12th May 2015)

• Record Type: Journal Article
• Authors: Hiltunen, Timo P.; Donner, Kati M.; Sarin, Antti‐Pekka; Saarela, Janna; Ripatti, Samuli; Chapman, Arlene B.; Gums, John G.; Gong, Yan; Cooper‐DeHoff, Rhonda M.; Frau, Francesca; Glorioso, Valeria; Zaninello, Roberta; Salvi, Erika; Glorioso, Nicola; Boerwinkle, Eric; Turner, Stephen T.; Johnson, Julie A.; Kontula, Kimmo K.
• Is Part Of: Journal of the American Heart Association. Volume 4:Issue 1(2015:Feb.)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2015-05-12
• Subjects: antihypertensive drug -- association study -- drug response -- genome‐wide -- hypertension; Heart -- Diseases -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; Cerebrovascular disease -- Periodicals; Cardiology -- Periodicals; 616.1
• DOI: 10.1161/JAHA.114.001521
• Languages: English
• ISSNs: 2047-9980

Abstract

Abstract : Background: Identification of genetic markers of antihypertensive drug responses could assist in individualization of hypertension treatment. Methods and Results: We conducted a genome‐wide association study to identify gene loci influencing the responsiveness of 228 male patients to 4 classes of antihypertensive drugs. The Genetics of Drug Responsiveness in Essential Hypertension (GENRES) study is a double‐blind, placebo‐controlled cross‐over study where each subject received amlodipine, bisoprolol, hydrochlorothiazide, and losartan, each as a monotherapy, in a randomized order. Replication analyses were performed in 4 studies with patients of European ancestry (PEAR Study, N=386; GERA I and II Studies, N=196 and N=198; SOPHIA Study, N=372). We identified 3 single‐nucleotide polymorphisms within the ACY3 gene that showed associations with bisoprolol response reaching genome‐wide significance ( P <5×10 −8 ); however, this could not be replicated in the PEAR Study using atenolol. In addition, 39 single‐nucleotide polymorphisms showed P values of 10 −5 to 10 −7 . The 20 top‐associated single‐nucleotide polymorphisms were different for each antihypertensive drug. None of these top single‐nucleotide polymorphisms co‐localized with the panel of >40 genes identified in genome‐wide association studies of hypertension. Replication analyses of GENRES results provided suggestive evidence for a missense variant (rs3814995) in the NPHS1 (nephrin) gene influencing losartan response, and for 2 variants influencing hydrochlorothiazide response, located within or close to the ALDH1A3 (rs3825926) and CLIC5 (rs321329) genes. Conclusions: These data provide some evidence for a link between biology of the glomerular protein nephrin and antihypertensive action of angiotensin receptor antagonists and encourage additional studies on aldehyde dehydrogenase–mediated reactions in antihypertensive drug action.